Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: Pembrolizumab and Radiotherapy in Locally Advanced NSCLC
NCT03523702Phase 2Completed
- Sponsor
- Montefiore Medical Center
- Start
- Aug 2018
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Progression-Free Survival at 12 months. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03523702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523702.